Provectus Pharmaceuticals Inc. President Timothy Scott, Ph.D., Receives "Distinguished Achievement Award" From University of Wisconsin

KNOXVILLE, Tenn., Oct. 20 /PRNewswire-FirstCall/ -- Provectus Pharmaceuticals, Inc. announced today that its President, Timothy Scott, Ph.D., has received the prestigious "Distinguished Achievement Award" from the College of Engineering of the University of Wisconsin, Madison. The award is presented to distinguished educators and alumni who have made significant contributions to science, industry, the school of engineering and the community. Dr. Scott received his doctorate in Chemical Engineering from the university.

Paul S. Peercy, Dean of the College of Engineering at the University of Wisconsin-Madison said, "Each year, the UW-Madison College of Engineering's nine academic departments nominate outstanding engineering alumni for honors based on their contributions to the engineering profession, the College of Engineering and society as a whole. Tim Scott provides a perfect example of the power of an engineering education."

Dr. Scott holds 17 U.S. patents and has published more than 70 peer- reviewed papers. Several of his innovations have been licensed to the oil, gas and biotechnology industries. He received the R&D 100 Award for creating a new industrial enzyme. He has also been the recipient of the National Laboratory Consortium Award for Excellence in Technology Transfer, the Inventor's Forum Advanced Technology Award and the Martin Marietta Energy Systems Inventor of the Year Award. Dr. Scott also has served as adjunct associate professor of chemical engineering at the University of Tennessee, Knoxville. Scott earned his bachelor's degree in chemical engineering from the University of Tennessee.

The award is scheduled to be presented to Dr. Scott at a ceremony in Madison on Friday, October 21. He is also scheduled to address engineering students at the university in conjunction with the upcoming annual invention competition.

Prior to his position at Provectus, Dr. Scott served in senior management positions at Photogen Technologies, Inc.; Genase LLC; and the Oak Ridge National Laboratory. He was a co-founder, senior scientist, vice president and chief operating officer for Photogen Technologies. Dr. Scott also served as Photogen's interim CEO and chairman during the company's restructuring. While working at Genase, his duties included design and licensing of recombinant DNA-derived and other enzyme-based products. Before that, as director of bioprocessing at the Oak Ridge National Laboratory, Scott achieved a national presence in the use of advanced biotechnology for the production of energy, fuels and chemicals.

About Provectus Pharmaceuticals, Inc.

Provectus Pharmaceuticals, Inc. is a pioneering pharmaceutical company actively engaged in the design, development, and marketing of pharmaceutical technologies for the treatment of breast cancer, liver cancer, and metastatic melanoma. In addition, Provectus is preparing to begin Phase 2 clinical studies for the Company's topical agent Xantryl(TM), a treatment for psoriasis.

The Company's offices and laboratory are located at 7327 Oak Ridge Highway, Suite A, Knoxville, TN 37931; telephone: 865-769-4011. For more information, contact the Company at or visit the corporate Web site:

This release and others statements issued or made from time to time by the company or its representatives contain comments that may constitute forward- looking statements. Those include statements regarding the intent, belief or current expectations of the company and members of its management teams, as well as the assumptions on which the statements are based. Prospective investors are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward- looking statements.

Provectus Pharmaceuticals, Inc.

CONTACT: Investors: Rene Caron, +1-949-474-4300,, ofAllen & Caron Inc for Provectus Pharmaceuticals Inc; or Peter Culpepper,+1-865-769-4011,, of Provectus Pharmaceuticals Inc.

Back to news